R&D tax credit optimization, Section 174 expense capitalization, and QSBS entity structuring for early-stage biotechnology and life sciences companies.
Biotech startups operate in a pre-revenue reality that most tax guidance is not written for: years of R&D spending before any product revenue exists, venture funding that carries its own tax complexity, and one of the most valuable but most misunderstood credits available to small companies, the R&D tax credit. Hasco Tax Advisors works with early-stage biotech and life sciences companies on the specific accounting and tax planning this stage of a company actually needs.
Qualified research expenses, wages for scientists and researchers, supplies used in R&D, and certain contract research costs, can generate a federal tax credit even for a company with no taxable income yet. Under current rules, qualified small businesses can apply up to $500,000 of the R&D credit against payroll tax liability instead of income tax, which means the credit can produce real cash value even for a company years away from profitability.
Current tax law requires research and experimental expenditures to be capitalized and amortized over five years (fifteen for foreign research) rather than deducted immediately, a significant change from how R&D spending was traditionally treated. This affects cash tax planning meaningfully for R&D-heavy companies and needs to be modeled carefully alongside the R&D credit itself.
Venture funding instruments common to biotech, convertible notes, SAFEs, preferred equity rounds, each carry different tax and accounting treatment. Getting the books right on how funding is recorded matters for cap table accuracy, future round negotiations, and eventual exit tax planning.
Qualified Small Business Stock (QSBS) treatment under Section 1202 can allow founders and early investors to exclude a substantial portion of capital gains on eventual sale, but it requires the company to be a C-Corporation from early on and specific holding period and gross asset requirements to be met. This needs to be considered at formation, not discovered years later when it is too late to qualify.
Qualified research expenses tracked and categorized in a way that supports both the R&D credit calculation and required Section 174 capitalization.
Monthly financials built around what an early-stage company and its investors actually need to see: burn rate, runway, and spending against budget.
Convertible notes, SAFEs, and equity rounds recorded correctly, keeping your books and cap table consistent with each other.
Entity structure reviewed early against QSBS requirements, so founders and early investors do not lose eligibility for this benefit by accident.
Join the individuals and business owners who trust Hasco Tax Advisors with their most important financial decisions. Your first consultation is completely free, and you will leave it with a clear, direct answer on what is needed and what it costs.